18F-FDG PET/CT代谢参数对新辅助免疫(化疗)治疗非小细胞肺癌病理缓解早期预测的诊断性能:系统评价与Meta分析
该系统评价与Meta分析检索截至2025年1月的文献,纳入16项研究,评估18F-FDG PET/CT代谢参数对新辅助免疫(化疗)治疗非小细胞肺癌主要病理缓解(MPR)和病理完全缓解(pCR)的预测性能。ΔSUVmax对MPR诊断性能均衡(敏感度0.92、特异度0.77、AUC 0.94),对pCR敏感度高(0.94)但特异度降低(0.57、AUC 0.86);PERCIST敏感度高(1.00)但特异度有限(0.67),PERCIST-max敏感度0.92、特异度0.94。ΔSULpeak、SULpeak-Post和ΔSULmax等参数研究数量有限,降低泛化性,需更大验证研究确认其诊断效用。
要点
- ΔSUVmax对MPR诊断性能均衡:敏感度0.92、特异度0.77、AUC 0.94。
- ΔSUVmax对pCR敏感度0.94但特异度降至0.57,AUC 0.86。
- PERCIST敏感度1.00但特异度0.67,PERCIST-max敏感度0.92、特异度0.94。
核心结论
- 研究支持ΔSUVmax作为MPR的可靠指标,但其对pCR的特异度仍有限。
- PERCIST的高敏感度有助于排除非缓解者。
- ΔSULpeak、SULpeak-Post和ΔSULmax等参数研究数量有限,降低泛化性,需更大验证研究确认其诊断效用。
研究设计与样本
- 系统评价与Meta分析,检索PubMed、Web of Science、Embase和Cochrane Library从建库至2025年1月的研究。
- 纳入评估预设18F-FDG PET/CT参数(PERCIST、PERCIST-max、ΔSUVmax、ΔSULpeak、ΔSULmax、ΔMTV、ΔTLG、治疗前/后SUVmax、治疗后SULmax/SULpeak)并报告病理结局的研究。
- 共16项研究符合纳入标准,采用QUADAS-2评估方法学质量,通过HSROC模型分析敏感度、特异度和异质性,采用Deeks检验评估发表偏倚。
主要发现
- 对MPR,PERCIST敏感度1.00但特异度0.67,PERCIST-max敏感度0.92、特异度0.94。
- ΔSUVmax对MPR敏感度0.92、特异度0.77、AUC 0.94;ΔSULpeak敏感度0.94、特异度0.91。
- ΔMTV对MPR敏感度0.77、特异度0.83;ΔTLG敏感度0.63、特异度0.81。
- 对pCR,ΔSUVmax敏感度0.94、特异度0.57、AUC 0.86;SUVmax-Pre敏感度0.78、特异度0.81。
- 亚组分析提示ΔSUVmax的诊断性能随治疗方案不同而变化。
关键数值与推荐
- MPR:PERCIST敏感度1.00、特异度0.67;PERCIST-max敏感度0.92、特异度0.94。
- MPR:ΔSUVmax敏感度0.92、特异度0.77、AUC 0.94;ΔSULpeak敏感度0.94、特异度0.91。
- MPR:ΔMTV敏感度0.77、特异度0.83;ΔTLG敏感度0.63、特异度0.81。
- pCR:ΔSUVmax敏感度0.94、特异度0.57、AUC 0.86;SUVmax-Pre敏感度0.78、特异度0.81。
临床怎么用
- 研究支持ΔSUVmax作为MPR的可靠指标,但其对pCR的特异度仍有限。
- PERCIST的高敏感度有助于排除非缓解者。
- ΔSULpeak、SULpeak-Post和ΔSULmax等参数研究数量有限,降低泛化性,需更大验证研究确认其诊断效用。
局限性
- ΔSULpeak、SULpeak-Post和ΔSULmax等参数研究数量有限,降低泛化性。
- 需更大验证研究确认上述参数的诊断效用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Early and accurate prediction of pathological response in non-small cell lung cancer (NSCLC) receiving neoadjuvant immune(chemo)immunotherapy is essential for guiding treatment strategies. This meta-analysis aims to assess the predictive performance of PET/CT-derived metabolic parameters for identifying major pathological response (MPR) and pathological complete response (pCR). METHODS: The PubMed, Web of Science, Embase, and Cochrane Library were searched for related studies from inception to January 2025. Studies assessed evaluated predefined 18F-FDG PET/CT parameter (PERCIST, PERCIST-max, ΔSUVmax, ΔSULpeak, ΔSULmax, ΔMTV, ΔTLG, pre/post-treatment SUVmax, post-treatment SULmax/SULpeak) and reported pathological outcomes were included. Methodological quality was evaluated using QUADAS-2. Sensitivity, specificity and heterogeneity were analyzed via HSROC models. Publication bias was assessed via Deeks' test. RESULTS: Sixteen studies met inclusion criteria. For MPR, PERCIST showed excellent sensitivity (1.00) but limited specificity (0.67), while PERCIST-max achieved both high sensitivity (0.92) and superior specificity (0.94). ΔSUVmax demonstrated balanced accuracy (sensitivity: 0.92; specificity: 0.77; AUC: 0.94), and ΔSULpeak also yielded high diagnostic performance (sensitivity: 0.94; specificity: 0.91). Volumetric metrics such as ΔMTV and ΔTLG showed variable results, with ΔMTV performing moderately (sensitivity: 0.77; specificity: 0.83), and ΔTLG exhibiting lower sensitivity (0.63) despite good specificity (0.81). For pCR, ΔSUVmax retained high sensitivity (0.94) but showed reduced specificity (0.57; AUC: 0.86). SUVmax-Pre showed moderate accuracy (sensitivity: 0.78; specificity: 0.81). Subgroup analyses indicated that the diagnostic performance of ΔSUVmax varied depending on treatment regimen. CONCLUSIONS: The study support ΔSUVmax as a reliable indicator of MPR, although its specificity for pCR remains limited. PERCIST's high sensitivity aids in excluding non-responders. However, limited study numbers for parameters like ΔSULpeak, SULpeak-Post, and ΔSULmax reduce generalizability, necessitating larger validation studies to confirm their diagnostic utility.
引用
- Deng H, Deng Z, Huang Y, et al. Diagnostic performance of 18F-FDG PET/CT metabolic parameters for early prediction of pathological response in NSCLC treated with neoadjuvant immuno(chemo)therapy: A systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2025. PMID: 40932611. doi:10.1007/s00259-025-07497-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。